An NIH phase II study of bevacizumab (VEGF antibody) plus erlotinib (EGFR inhibitor) reported a 72% confirmed response rate in advanced HLRCC-associated kidney cancers [49], with median rPFS of 21 months, indicating substantial activity in this aggressive subtype. Here, EGFR is linked to hereditary leiomyomatosis and renal cell cancer.